Mei Chen

Dr. Mei Chen


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Clinics in Dermatology
Verified
Journal Article
Open access
RGRishu Gupta
Rishu Gupta
DWDavid T. Woodley
David T. Woodley
MCMei Chen
Mei Chen
Epidermolysis bullosa acquisita (EBA) is a rare, acquired, chronic subepidermal bullous disease of the skin and mucosa characterized by autoantibodies to type VII collagen (C7) structures, a major component of anchoring fibrils, which attach the epidermis to the dermis. EBA patients have tissue-bound and circulating antitype C7 autoantibodies that attack type C7 and result in a reduction or perturbation of normally functioning anchoring fibrils. Patients with EBA have skin fragility, blisters, erosions, scars, milia, and nail loss, all features reminiscent of genetic dystrophic epidermolysis bullosa. These immunoglobulin G antitype C7 antibodies are pathogenic, because when they are injected into mice, the mice develop an EBA-like blistering disease. In addition to the classical mechanobullous presentation, EBA also has several other distinct clinical syndromes similar to bullous pemphigoid, Brunsting-Perry pemphigoid, or cicatricial pemphigoid. Although treatment for EBA is often unsatisfactory, some therapeutic success has been achieved with colchicine, dapsone, plasmapheresis, photopheresis, infliximab, and intravenous immunoglobulin.

1 January 2009 in Molecular Therapy
Verified
Journal Article
Open access
JRJennifer Remington
Jennifer Remington
Xinyi WangXinyi Wang
Xinyi Wang
YHYingpin Hou
Yingpin Hou
HZHui Zhou
Hui Zhou
JBJulie Burnett
Julie Burnett
MCMei Chen
Mei Chen
Patients with recessive dystrophic epidermolysis bullosa (RDEB) have incurable skin fragility, blistering, and scarring due to mutations in the gene that encodes for type VII collagen (C7) that mediates dermal–epidermal adherence in human skin. We showed previously that intradermal injection of recombinant C7 into transplanted human DEB skin equivalents stably restored C7 expression at the basement membrane zone (BMZ) and reversed the RDEB disease features. In this study, we evaluated the feasibility of protein therapy in a C7 null mouse (Col7a1–/–) which recapitulates the features of human RDEB. We intradermally injected purified human C7 into DEB mice and found that the injected human C7 stably incorporated into the mouse BMZ, formed anchoring fibrils, and corrected the DEB murine phenotype, as demonstrated by decreased skin fragility, reduced new blister formation, and markedly prolonged survival. After 4 weeks, treated DEB mice developed circulating anti-human C7 antibodies. Most surprisingly, these anti-C7 antibodies neither bound directly to the mouse's BMZ nor prevented the incorporation of newly injected human C7 into the BMZ. Anti-C7 antibody production was prevented by treating the mice with an anti-CD40L monoclonal antibody, MR1. We conclude that protein therapy may be feasible for the treatment of human patients with RDEB.

10 July 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DWDavid T. Woodley
David T. Woodley
JCJon Cogan
Jon Cogan
YHYingping Hou
Yingping Hou
CLChao Lyu
Chao Lyu
MMM. Peter Marinkovich
M. Peter Marinkovich
MCMei Chen
Mei Chen
BACKGROUND. Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF). We previously demonstrated that gentamicin produced functional type VII collagen in RDEB cells harboring nonsense mutations. Herein, we determined whether topical or intradermal gentamicin administration induces type VII collagen and AFs in RDEB patients. METHODS. A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations. The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily at 2 open erosion sites for 2 weeks. The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients. Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment. A secondary outcome assessed wound closure of topically treated erosions. RESULTS. Both topical and intradermal gentamicin administration induced type VII collagen and AFs at the dermal-epidermal junction of treatment sites. Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months. Topical gentamicin corrected dermal-epidermal separation, improved wound closure, and reduced blister formation. There were no untoward side effects from gentamicin treatments. Type VII collagen induction did not generate anti–type VII collagen autoantibodies in patients’ blood or skin. CONCLUSION. Topical and intradermal gentamicin suppresses nonsense mutations and induces type VII collagen and AFs in RDEB patients. Gentamicin therapy may provide a readily available treatment for RDEB patients with nonsense mutations. TRIAL REGISTRATION. ClinicalTrials.gov NCT02698735. FUNDING. Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH, and VA Merit Award.

1 May 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
DWDavid T. Woodley
David T. Woodley
CCCarl Chang
Carl Chang
PSPayam Saadat
Payam Saadat
RRRamin Ram
Ramin Ram
ZLZhi Liu
Zhi Liu
MCMei Chen
Mei Chen

1 July 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
DWDavid T. Woodley
David T. Woodley
Xinyi WangXinyi Wang
Xinyi Wang
MAMahsa Amir
Mahsa Amir
BHBrian Hwang
Brian Hwang
JRJennifer Remington
Jennifer Remington
MCMei Chen
Mei Chen
Type VII collagen (C7) is located in the skin between its two main layers, the epidermis and the dermis, where it forms structures, anchoring fibrils (AFs), which are necessary for epidermal–dermal adherence ( Sakai et al., 1986 Sakai L.Y. Keene D.R. Morris N.P. et al. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol. 1986; 103 : 1577-1586 Crossref PubMed Scopus (376) Google Scholar ; Burgeson, 1993 Burgeson R.E. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol. 1993; 101 : 252-255 Abstract Full Text PDF PubMed Google Scholar ). The COL7A1 gene encodes for a 290-kDa alpha chain ( Christiano et al., 1994 Christiano A.M. Greenspan D.S. Lee S. et al. Cloning of human type VII collagen: complete primary sequence of the α1(VIII) chain and identification of intragenic polymorphisms. J Biol Chem. 1994; 269 : 20256-20262 PubMed Google Scholar ). C7 is composed of three alpha chains that form a homotrimer of ∼900 <!----> kDa. Within the extracellular space, C7 molecules form antiparallel dimers, which aggregate laterally to form AFs. C7 has some unusual properties that make it quite distinctive from other collagens, such as its solubility in neutral buffers. Most skin-associated collagens such as type I collagen induce platelet aggregation and clot formation when exposed to the blood stream, whereas C7 does not ( Saelman et al., 1994 Saelman E.U. Nieuwenhuis H.K. Hese K.M. et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood. 1994; 83 : 1244-1250 PubMed Google Scholar ).

1 June 2006 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
DWDavid T. Woodley
David T. Woodley
RRRamin Ram
Ramin Ram
ADArvin Doostan
Arvin Doostan
PBPubali Bandyopadhyay
Pubali Bandyopadhyay
YHYi Huang
Yi Huang
MCMei Chen
Mei Chen